Ipilimumab for Patients with Relapse after Allogeneic TransplantationMatthew S. Davids, Robert J. Soiffer, Haesook T. Kim et al.|New England Journal of Medicine|2016Cited by 595
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialPhilippe Armand, Leo I. Gordon, Arnon Nagler et al.|Journal of Clinical Oncology|2013Cited by 439
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, William A. Wood, Michael J. Martens et al.|Blood|2017Cited by 296
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphomaMatthew J. Frigault, Marcela V. Maus, Jörg Dietrich et al.|Blood|2019Cited by 237
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid LeukemiaYi‐Bin Chen, Robert J. Soiffer, Shuli Li et al.|Biology of Blood and Marrow Transplantation|2014Cited by 234